Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Early Phase 1
1(33.3%)
3Total
Phase 2(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04839575Phase 2Terminated

Study of Latiglutenase in T1D/CD Patients

Role: collaborator

NCT03011931Early Phase 1Completed

Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]

Role: collaborator

NCT03585478Phase 2Completed

Latiglutenase as a Treatment for Celiac Disease

Role: lead

All 3 trials loaded